Panel Discussion: Advances in the Development of Muscarinic Agonists – Learnings from Clinical Trials, Addressing Biology & Subtype Selectivity

Time: 10:00 am
day: Day One

Details:

  •  What can we learn from the failure of Emraclidine? What can we decipher from post-mortem analyses? How much of a role did trial oversight and placebo responses influence the results of the EMPOWER trials?
  • Understanding Subtype-Specific Functions. Is M1 and M4 receptor agonism necessary for efficacy?

Speakers: